Drug search by name

Amphocin and Renal dysfunction

Result of checking the interaction of drug Amphocin and disease Renal dysfunction for safety when used together.

Check result:

Amphocin <> Renal dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Intravenously administered amphotericin B is nephrotoxic and may commonly cause decreased renal function and abnormalities including azotemia, hypo- and hyperkalemia, hypomagnesemia, hyposthenuria, renal tubular acidosis, and nephrocalcinosis. Renal function should be closely monitored in all patients receiving intravenous therapy with amphotericin B but in particular, patients with preexisting renal impairment. Dosage reductions are recommended. Serum creatinine, BUN, potassium and magnesium levels should be evaluated frequently, and dosing adjusted or discontinued accordingly.

References:

Fisher MA, Talbot GH Maislin G, McKeon BP, Tynan KP, Strom BL "Risk factors for amphotericin B-associated nephrotoxicity." Am J Med 87 (1989): 547-52
Keane WF, Everett ED, Golper TA, Gokal R, Halstenson C, Kawaguchi Y "Peritoneal dialysis-related peritonitis treatment recommendations: 1993 update." Perit Dial Int 13 (1993): 14-28
"Product Information. Fungizone (amphotericin B)." Bristol-Myers Squibb, Princeton, NJ.
Chabot GG, Pazdur R, Valeriote FA, Baker LH "Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients." J Pharm Sci 78 (1989): 307-10
Bullock W, Luke R, Nuttall C, Bhathena D "Can mannitol reduce amphotericin B nephrotoxicity?" Antimicrob Agents Chemother 10 (1976): 555-63
Morgan DJ, Ching MS, Raymond K, et al "Elimination of amphotericin B in impaired renal function." Clin Pharmacol Ther 34 (1983): 248-53
Branch R "Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation." Arch Intern Med 148 (1988): 2389-94
Sacks P, Fellner S "Recurrent reversible acute renal failure from amphotericin." Arch Intern Med 147 (1987): 593-5
Arning M, Scharf R, Schneider W "Prevention of renal failure during long-term treatment with amphotericin-B." Klin Wochenschr 65 (1987): 1108
McCurdy D, Frederic M, Elkinton JR "Renal tubular acidosis due to amphotericin B." N Engl J Med 268 (1968): 124-31
"Amphotericin." Med Lett Drugs Ther 30 (1988): 30-2
Branch R, Jackson E, Jacqz E, et al "Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline." Klin Wochenschr 65 (1987): 500-6
Patterson R, Ackerman G "Renal tubular acidosis due to amphotericin B nephrotoxicity." Arch Intern Med 127 (1971): 241-4
Rosch J, Pazin G, Fireman P "Reduction of amphotericin B nephrotoxicity with mannitol." JAMA 235 (1976): 1995-6
Barton C, Pahl M, Vaziri N, Cesario T "Renal magnesium wasting associated with amphotericin B therapy." Am J Med 77 (1984): 471-4
Clements J, Peacock J "Amphotericin B revisited: reassessment of toxicity." Am J Med 88 (1990): n22-7